Søby, S., Prestwich, R., Gyldenkerne, N., Maare, C., Lonkvist, C. K., Andersen, M., Nowicka-Matus, K., Gothelf, A.
, Tramm, T., Toustrup, K., Mihaela, S., Ulahannan, D., Iyizoba-Ebozue, Z.
& Eriksen, J. G. (2025).
Pembrolizumab as first-line treatment for recurrent or metastatic head and neck squamous cell carcinoma: a multi-institutional DAHANCA cohort study.
Acta Oncologica,
64, 1269-1275.
https://doi.org/10.2340/1651-226X.2025.44327
Mondin, A., Barbot, M., Ceccato, F., Pereira, A. M., Angelousi, A., Elenkova, A., Zilaitiene, B., Schalin-Jäntti, C., De Herdt, C., Kanaka-Gantenbein, C., Maiter, D., Gatto, F., Johannsson, G.
, Stochholm, K., Bugalho, M. J., Detomas, M., Reincke, M., Toumba, M., Giordano, R. ... Scaroni, C. (2025).
European survey on metabolic and cardiovascular risk in Cushing syndrome.
Journal of Endocrinological Investigation,
48(11), 2657-2670.
https://doi.org/10.1007/s40618-025-02663-9
Baygi, F., Brandt, C. J., Kjær-Hansen, K., Grøntved, A., Brønd, J. C.
, Nicolaisen, S. K., Stidsen, J. V.
, Thomsen, R. W., Søndergaard, J. & Nielsen, J. S. (2025).
Participation of individuals with type 2 diabetes in a behavioural e-health lifestyle intervention in Denmark: A feasibility study.
Diabetes Epidemiology and Management,
19-20, Article 100285.
https://doi.org/10.1016/j.deman.2025.100285
Højte, C., Olsen, M. F., Faurholt-Jepsen, D., Jørgensen, M. H., Pressler, T., Leo-Hansen, C., Bryrup, T.
, Jeppesen, M., Olesen, H. V., Petersen, J., Katzenstein, T. L., Nielsen, B. U., Skov, M. & the TransformCF study group (2025).
Severe hepatotoxicity is uncommon following the introduction of Elexacaftor/Tezacaftor/Ivacaftor: A real-world two-years follow-up study of the Danish cystic fibrosis cohort.
Journal of Cystic Fibrosis,
24(5), 998-1005.
https://doi.org/10.1016/j.jcf.2025.08.008